An Iranian knowledge-based company succeeded in producing injection pens that are equal in quality to similar foreign ...

— Are you looking for the complete & verified bond data? — We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock ...

Possible problems: Research has found that a true growth hormone deficiency in your older years reduces strength and raises your risk of heart disease. But while growth hormone production declines ...

Growth hormone treatment is a safe and effective therapy that’s often used to treat children and adults with a deficiency in human growth hormone (also known as HGH or somatropin). Naturally ...

Penumbra (PEN) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks ...

PEN is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of A and VGM Score of B. Earnings are expected to grow 34.5% year-over-year for the current fiscal year, with sales growth of 12.5%.

It has a broad portfolio that addresses challenging medical conditions in markets with significant unmet needs. PEN is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of A and VGM Score of B.